Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

CLARITY Causative Link between respirAtory syncytial viRus and chronic lung diseases: Identifying Targets for therapY

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€7.1m
Total cost
€7.1m
Partners
9 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101137201

What the project is doing

In the project's own words, from its summary on CORDIS.

Chronic respiratory diseases are non-communicable diseases for which infections by several respiratory viruses and human genetics constitute major risk factors. The molecular and physiological mechanisms of how these viral infections cause and contribute to non-communicable disease development are unknown. Respiratory syncytial virus (RSV) is a virus that infects nearly all infants before the age of 2 years and that is linked to asthma development.

We propose an integrative approach to identify genetic risk factors and mechanisms underlying virus-induced asthma. Specifically, using two national cohorts (Estonian and Spanish), we will identify human genetic risk factors and RSV strains that contribute to severe bronchiolitis. We analyse how RSV perturbs intracellular networks to change cellular properties that trigger asthma development. We will use Artificial Intelligence (AI)-based techniques to integrate generated data with the current biological knowledge, to generate RSV-induced perturbation signatures and to identify drug-like compounds able to revert the effects of the RSV-induced perturbations.

We will validate both mechanisms and candidate compounds in patient derived airway organoid models and, when promising, in a controlled human infection model trial. CLARITY will impact the understanding, prevention and possibly treatment of virus-triggered asthma. The results will enable development of a genetic risk score for long-term asthma development that enables personalised prevention campaigns, which will be developed jointly with patient groups.

The molecular mechanisms discovered, and the drug-like compounds that revert the perturbation signatures, will enable development of mechanism-targeted drugs. Fundamentally, the mechanisms identified in this specific model for a strong viral contribution to non-communicable disease will likely represent general mechanisms of how viral infections cause onset and development of other non-communicable diseases.

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Tartu UlikoolTartuEstoniaParticipant
Fundacio Institut De Recerca Biomedica (irb Barcelona)BarcelonaSpainParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La PazMadridSpainThird party
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro-MajadahondaMajadahondaSpainThird party
Instituto De Salud Carlos IiiMadridSpainParticipant
Servicio Madrileno De SaludMadridSpainParticipant
Stichting ResvinetZeistNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI